IMAXIO SA Company Profile
Imaxio develops therapeutic and theranostic products that address currently unmet medical needs, particularly in the field of infectious diseases and oncology. Our integrated infrastructure enables in-house development, production and marketing of vaccines.
Our development is based on a core growth served by our product and services to the industry. We also strive to strengthen our company through active Mergers and Acquisitions activities in order to sustain internal R&D programs and acquire synergistic products or technologies.
Imaxio originally started in September 2000 as a spin-off company - called Avidis - from the Medical Research Council and Cambridge University (UK). The company developed a recombinant protein refolding technology and OverExpress® competent cells for the expression of recombinant proteins. More applications of this technology were developed during the next four years, before reengineering of the company in 2004 with the purpose to focus on vaccines.
In 2006, Avidis and Diagnogene joined forces to become Imaxio. Later in the year, Imaxio further strengthened its presence in the protein engineering industry through the acquisition of the peptide aptamer technology assets from a French company called Aptanomics.
In order to sustain its strategy based on the combination of commercial and R&D activities, Imaxio has developed successful drug discovery and genomic services to the industry.
In early 2009, Imaxio acquired Axcell Biotechnologies, a French biopharmaceutical company.
Location
Biopole Clermont-Limagne
Saint-Beauzire
63360
France
Contact
Phone: 33(0)473 64 43 90
Fax: 33(0)473 64 43 93
Email: contact@imaxio.com
News Articles
Imaxio galvanisée par un véto qui dit oui
Voici un premier pas qui pèse lourd pour la biotech lyonnaise Imaxio. La firme vient de signer un accord d’option de licence…
D&A Pharma, Imaxio sales and marketing update
Investments in CMO activities: round up
Outsourcing-Pharma.com presents a round-up of the latest contract manufacturing investments, including new screening services for Imaxio, Encap’s renewed push for its CMO biz, and Pernix’s bid to...
Imaxio acquires orphan drug indicated for congenital metabolic disease
Imaxio, a biopharmaceutical company specialising in vaccines and genomics, has acquired Trolovol (D-penicillamine), a drug indicated for an orphan congenital metabolic disease. The product previously...
Dezima Pharma in-licenses CETP inhibitor; Imaxio acquires Trolovol
Netherlands-based biotech firm Dezima Pharma says it has in-licensed a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Japanese drug major Mitsubishi Tanabe Pharma...
Lyonbiopôle, worldwide health & biotech competitiveness cluster, focused on infectious diseases and cancers, invites you to join them on April, 22nd 2013 from 7.30 am to 2.00...
Drugs and Medications
None
PubMed Articles
None
Clinical Trials
None
Companies
Imaxio develops therapeutic and theranostic products that address currently unmet medical needs, particularly in the field of infectious diseases and oncology. Our integrated infrastructure enables...
More Information about "IMAXIO SA" on BioPortfolio
We have published hundreds of IMAXIO SA news stories on BioPortfolio along with dozens of IMAXIO SA Clinical Trials and PubMed Articles about IMAXIO SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of IMAXIO SA Companies in our database. You can also find out about relevant IMAXIO SA Drugs and Medications on this site too.
